Topoisomerase inhibitors with antibacterial and anticancer activity

Paul J Hergenrother (Inventor), Andrew Riley (Inventor)

Research output: Patent


Herein is described the conversion of deoxynybomycin (DNM), a natural product and DNA gyrase inhibitor with minimal cytotoxicity, into a compound (Formula I) that has anticancer activity. Detailed in vitro and cell culture experiments demonstrate that these compounds inhibit Top2 and also act upon topoisomerase I. Similar approaches are applicable to other classes of gyrase inhibitors and other antibacterial targets for discovery of new anticancer drugs.
Original languageEnglish (US)
U.S. patent number11274106
Filing date6/21/18
StatePublished - Mar 15 2022


Dive into the research topics of 'Topoisomerase inhibitors with antibacterial and anticancer activity'. Together they form a unique fingerprint.

Cite this